Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance-Reference-Cited by-同舟云学术

Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance

Published:2017-07-16 Issue:5 Volume:121 Page:442-446
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharmacol Toxicol

Author:

Cid-Silva Purificación¹²,Llibre Josep M.³,Fernández-Bargiela Noelia²,Margusino-Framiñán Luis¹²,Balboa-Barreiro Vanesa⁴,Pernas-Souto Berta¹,Martín-Herranz Isabel²,Castro-Iglesias Ángeles¹,Poveda Eva¹

Affiliation:

1. Division of Clinical Virology; Biomedical Research Institute of A Coruña (INIBIC); Universitary Hospital of A Coruña (CHUAC); SERGAS; University of A Coruña (UDC); A Coruña Spain

2. Service of Pharmacy; Universitary Hospital of A Coruña (CHUAC); SERGAS; A Coruña Spain

3. Infectious Diseases Service and ‘Fight AIDS’ Foundation; Hospital Universitari Germans Trias i Pujol; Barcelona Spain

4. Clinical Epidemiology and Biostatistics Unit; Biomedical Research Institute of A Coruña (INIBIC); Universitary Hospital of A Coruña (CHUAC); SERGAS; University of A Coruña (UDC); A Coruña Spain

Funder

Fondo de Investigación Sanitaria

Fundación Professor Novoa Santos

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcpt.12828/fullpdf

Reference19 articles.

1. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

2. Panel Members of European AIDS Clinical Society (EACS) European Guidelines for treatment of HIV-positive adults in Europe version 8.0 http://www.eacsociety.org/files/guidelines_8.0-english.pdf

3. Panel de expertos de GeSIDA y Plan Nacional sobre el Sida Documento de consenso de GesiDa/Plan nacional sobre el sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2017) http://gesida-seimc.org/contenidos/guiasclinicas/2017/gesida-guiasclinicas-2017-TAR.pdf

4. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks;Sax;Lancet,2012

5. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial;DeJesus;Lancet,2012

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review;Expert Review of Anti-infective Therapy;2023-04-20

2. HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment;Pharmaceuticals;2022-12-09

3. Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study;AIDS Research and Therapy;2022-04-02

4. Relationship of sleep disorders with long-term complications and health-related quality of life in people with well-controlled human immunodeficiency virus;Medicine;2022-03-18

5. Clinical experience with dolutegravir: efficacy, safety, and tolerability;HIV & AIDS Review;2022